Document:

EX-10.3

 Exhibit 10.3 

FORM OF OFFER 
 TO
DIRECTORS, OFFICERS OR SPECIFICALLY DESIGNATED PERSONS 
 TO SUBSCRIBE LIABILITY INSURANCE AND PROVIDE INDEMNIFICATION 

WHEREAS 
 The public offering in the United States by DBV
Technologies (the “Company”) of shares in the form of American Depositary Shares (“ADSs”), two ADSs representing one ordinary share of the Company, the filing of forms with the Securities and Exchange Commission
(“SEC”) in connection with such public offering and the quotation of the ADSs on the Nasdaq Global Market (“Market”) expose the directors and the officers of the Company to major and specific risks with respect to
their service to the Company. 
 The Company, taking into account the scope of the obligations and possible personal liability of the directors and officers
induced by the U.S. securities laws and the fact that they are significantly more burdensome than under French law, has resolved that the said directors and officers should not be exposed to such personal liability. 

Moreover, in the United States, directors and officers are typically indemnified or insured. As a result, the Company has concluded that in the absence of
such protection against risks sustained by reason of the fact that they are serving as such, individuals might not accept to serve as directors or officers of the Company or might resign from their office. The Company has also concluded that it is
necessary to have such individuals serve on its board of directors and as its officers if it is to achieve its objectives in the international financial and commercial markets. 

It is the Company’s intention to provide said directors and officers with indemnification against liabilities and advancement of expenses in connection
with any matters that arise out of their service to the Company to the fullest extent permitted by applicable laws and regulations. 
 Accordingly,
considering as well the fact that the quotation of the ADSs on the Market is a key factor to the future development of the Company, the Company resolved that providing insurance coverage, indemnification and advancement of expenses to said directors
and officers to the fullest extent permitted by applicable laws and regulations is consistent with the Company’s corporate interest. 
 The undersigned
may also have certain rights to indemnification and/or insurance provided by a private equity fund, venture capital fund, an investment company and certain of their affiliates which have invested in the Company (collectively, the “Fund
Indemnitors”) which the undersigned and the Fund Indemnitors intend to be secondary to the primary obligation of the Company to indemnify undersigned as provided herein, with the Company’s acknowledgement and agreement to the foregoing
being a material condition to undersigned’s willingness to serve as director of the Company to the extent applicable. 

 NOW THEREFORE, THE COMPANY HEREBY IRREVOCABLY UNDERTAKES AS FOLLOWS: 

1. Beneficiary 
 The persons, whether individuals or
corporations, who may benefit from and accept the offer (the “Offer”) are: 
 (i) a director (a “Director”) of the
Company, and 
 (ii) the Chairman of the Board, the Directeur Général, a Directeur Général Delegué as well
as any executive officer, who is not a director, employed by the Company to whom the Board of Directors of the Company would elect to make the Offer (an “Officer”). 

A “Beneficiary”, for the purpose of the Offer, shall be a Director or an Officer having accepted and signed this Offer. 

2. Undertaking to Subscribe; Insurance Policy; Indemnification  

2.1. Upon acceptance and signature of this Offer by a Beneficiary, the Company shall immediately provide to the Beneficiary the benefit of one or more director
and officer (“D&O”) insurance policies (collectively, the “D&O Insurance Policy”) subscribed with a well-rated insurance company of national or international repute (the “Insurance Company”)
providing D&O insurance coverage in line with best practice for companies in the United States with a similar market capitalization and industry to the Company (“Best Practices”), to the fullest extent permitted by applicable
laws and regulations. Any losses incurred by the Beneficiary for any damages, losses, liabilities, judgments, fines, penalties (whether civil, criminal or other) and amounts paid in settlement (if such settlement is approved in advance by the
Company, which approval shall not be unreasonably withheld), including without limitation all interest, assessments and other charges paid or payable in connection with or in respect of any of the foregoing (collectively, the
“Losses”) if the Beneficiary is or was or becomes a party to or witness or other participant in, or is threatened to be made a party to or witness or other participant in, any threatened, pending or completed claim, demand, action,
suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative, investigative or other, whether formal or informal, or any inquiry or investigation, whether made, instituted or conducted by the Company or any
other party, including without limitation any foreign, federal, state or other governmental entity by reason of (or arising in part out of) any event or occurrence related to the fact that the Beneficiary is or was a Director or Officer of the
Company, or any Subsidiary of the Company (as defined below), or is or was serving at the request of the Company as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action or
inaction on the part of the Beneficiary while serving in such capacity, shall be referred hereunder, collectively, as an “Indemnifiable Claim”. The Beneficiary shall be compensated for any Indemnifiable Claim by this D&O
Insurance Policy or if not indemnifiable thereunder, by the Company to the fullest extent permitted by law. Also to the fullest extent permitted by applicable laws and regulations, the D&O Insurance Policy shall provide for indemnification of
the Beneficiary in line with Best Practices against reasonable and necessary Expenses (as defined) as a result of the facts, acts or omission described above, in the event the Beneficiary was, is or is threatened to be made, a party or witness or
participant in, by whatever means, a hearing or investigation which the Beneficiary in good faith and reasonably thinks could lead to an action or other relief, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal,
administrative, or other, whether formal or informal. 

  
 2. 

 For purposes of this Agreement, a “Subsidiary” shall mean an entity, which the Company directly
or indirectly controls, 50% or more of the entity’s voting securities. 
 For the purpose of the Offer, a “Claim” means (1) any
threatened, asserted, pending or completed claim, demand, action, suit or proceeding, whether civil, criminal, administrative, arbitrative, investigative or other, and whether made pursuant to foreign federal, state or other law; and (2) any
inquiry or investigation, whether made, instituted or conducted by the Company or any other party, including without limitation any foreign, federal, state or other governmental entity, that Beneficiary determines might lead to the institution of
any such claim, demand, action, suit or proceeding. 
 To the fullest extent permitted by applicable laws and regulations, the D&O Insurance Policy
shall provide for indemnification of the Beneficiary in line with Best Practices against reasonable and necessary expenses (including attorneys’ fees and all other costs, expenses and expenses incurred in connection with investigating,
defending, being a witness in or participating in (including on appeal), or preparing to defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution mechanism, hearing, inquiry or investigation)
(collectively, hereinafter “Expenses”) and any and all Losses in connection with an Indemnifiable Claim. 
 The Company shall in the first
instance pay on behalf of the Beneficiary any deductible or retention amounts due under the Insurance Policy in connection with any Indemnifiable Claim or Claim for the payment of Expenses, to the fullest extent permitted by applicable laws and
regulations. 
 2.2. As a result of the acceptance and signature of this Offer by the Beneficiary, a bilateral contract will be formed between the Company
and the Beneficiary. 
 2.3. To the fullest extent permitted by applicable laws and regulations, the Company agrees that, so long as a Director or Officer
shall continue to serve as a Director or Officer of the Company or any Subsidiary, or shall continue at the request of the Company to serve as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, and
thereafter so long as a Director or Officer shall be subject to any possible Indemnifiable Claim by reason of the fact that said Director or Officer was a Director or Officer of the Company or any Subsidiary or at the request of the Company to serve
as a director or officer of another corporation, partnership, joint venture, trust or other enterprise, and thereafter, the Company will maintain in effect for the benefit of such Director or Officer one or more valid, binding and enforceable
insurance policies with the Insurance Company providing coverage, including with respect to limits of liability thereunder, at least comparable to that provided in this Offer, and such insurance policy or policies shall be or be deemed to be the
D&O Insurance Policy for all purposes of this Offer. 
 3. Exclusions 

The Beneficiary acknowledges that French law contains material limitations on indemnification or coverage for Losses and/or Expenses and currently prevents the
Company, in particular, from indemnifying the Beneficiary for Losses and Expenses incurred by a Beneficiary with respect to the following Claims: 
 (i) any
Claim made by the Company or by a shareholder or any other person on behalf of the Company (derivative action); 
 (ii) any Claim relating to remuneration
paid to the Beneficiary, if it shall be determined that such remuneration was not due; 

  
 3. 

 (iii) any Claim for which a judgment is rendered against the Beneficiary for an accounting of profits made from
the purchase or sale of, or the procurement to purchase or sell, securities of the Company pursuant to insider trading laws or regulations; 
 (iv) any
Claim which is based on the Beneficiary’s willful or gross misconduct or on a fraud or a fraudulent misrepresentation, intentional or fraudulent (or deemed to be so) misconduct, whether the Beneficiary has acted alone or as an accomplice if it
should be finally determined that the Beneficiary is guilty of such misconduct; or 
 (v) any Claim which is based on the Beneficiary’s criminal
actions. 
 The Beneficiary further acknowledges that the D&O Insurance Policy contains or may contain similar limitations on coverage for Losses or
Expenses incurred by a Beneficiary, in each case with respect to Indemnifiable Claims, and that it does not cover Claims (i) pending, if any, at the date this Offer is accepted and signed by the relevant Beneficiary, (ii) which arise from
the settlement of any action or Claim without the Company’s written consent or, generally, that cannot be insured under applicable laws and regulations; 

provided that the terms of the D&O Insurance Policy shall determine whether insurance coverage is available to the Beneficiary in connection with any
Indemnifiable Claim, and that any limitations, restrictions or exclusions contained in the Insurance Policy that are not mandated by applicable law shall not relieve the Company of its obligation to provide indemnification to the Beneficiary for
Losses and Expenses in each case with respect to Indemnifiable Claims to the fullest extent permitted by applicable laws and regulations. 
 4.
Notification and Defense of an Indemnifiable Claim 
 4.1. As soon as practicable after the written receipt by the Beneficiary of a Indemnifiable
Claim, the Beneficiary shall notify the Company in writing thereof, which notification shall specify: 
  

	•	 	the existence and the nature of the Indemnifiable Claim; and 

  

	•	 	the nature and the estimate of the amount of the Losses and Expenses with respect to an Indemnifiable Claim. 

Omission so to notify the Company will not relieve the Company from liability under the Offer, except if thereby the Company has been materially prejudiced.

 4.2. In the event the Company shall be requested by Beneficiary to pay the Expenses or Losses of any Indemnifiable Claim, the Company, if appropriate,
shall be entitled to assume the defense of such Indemnifiable Claim, or to participate to the extent permissible in such Indemnifiable Claim, with counsel reasonably acceptable to Beneficiary. Upon assumption of the defense by the Company and the
retention of such counsel by the Company, the Company shall not be liable to Beneficiary under this Agreement for any Expenses of counsel subsequently incurred by Beneficiary with respect to the same Indemnifiable Claim, provided that Beneficiary
shall have the right to employ separate counsel in such Indemnifiable Claim at Beneficiary’s sole cost and expense. Notwithstanding the foregoing, if Beneficiary’s counsel delivers a written notice to the Company stating that such counsel
has reasonably concluded that there may be a conflict of interest between the Company and Beneficiary in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such
Indemnifiable Claim within a reasonable time, then in any such event the fees and expenses of Beneficiary’s counsel to defend such Indemnifiable Claim shall be subject to the indemnification and advancement of Expenses provisions of this
Agreement. 

  
 4. 

 No settlement of any Claim shall be agreed upon and entered into without the Company’s prior written
consent, not to be unreasonably withheld. By default of such Company’s prior written consent, the Company will be relieved from any and all liability for such settlement of a Indemnifiable Claim, if thereby the Beneficiary has been excluded
from D&O Insurance Policy coverage or benefit and/or if thereby the Company has been materially prejudiced. 
 5. Advance on Reimbursement of
Expenses 
 (a) To the fullest extent permitted by applicable laws and regulations and provided always that the Beneficiary has acted in good faith
and within his or her capacities as a Director or Officer of the Company, the Expenses reasonably incurred by the Beneficiary in defending or investigating any Indemnifiable Claim duly notified to the Company shall be paid by the Insurance Company
or by default if any payment demand to the Insurance Company remains unsatisfied after 30 days, as well as if the maximum insurance coverage under such D&O Policy is exceeded, by the Company, in advance of a final determination of the matter
upon the request of the Beneficiary, upon presentation of satisfactory evidence that such Expenses have been incurred and remittance to the Insurance Company or, as the case may be, the Company of Beneficiary’s written commitment to repay these
Expenses in the event that it is ultimately determined that the Beneficiary is not entitled to have these Expenses reimbursed; 
 provided that the Company
shall not be liable for that portion of such Expenses actually provided to the Beneficiary under the D&O Insurance Policy (to the fullest extent permitted by applicable laws and regulations, such undertaking shall be accepted without reference
to the financial ability of the Beneficiary to make repayment and any advances and undertakings to repay pursuant to this Section 5 shall be unsecured and interest-free); and provided further that no indemnification shall be permitted
(A) in the event that is finally determined that : (i) the Beneficiary’s conduct forming the subject matter of the Indemnifiable Claim was not consistent with the corporate interests of the Company; (ii) the Beneficiary’s
conduct was in bad faith, knowingly fraudulent or deliberately dishonest or constituted willful misconduct or (B) in respect of Indemnifiable Claims initiated or brought by Beneficiary against the Company or its directors, officers, employees
or other agents and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or otherwise available to Beneficiary under another agreement or applicable law. 

(b) The termination of any Claim pursuant to a Indemnifiable Claim by judgment, order, settlement, conviction or upon a plea of nolo contendere or its
equivalent, shall not, absent specific findings in respect of Beneficiary in the judgement, conviction of the Beneficiary or an acknowledgment by the Beneficiary in the settlement itself, create a presumption that the Beneficiary did not act in good
faith and in a manner that the Beneficiary reasonably believed to be in, or not opposed to, the best interests of the Company, and, with respect to any criminal proceeding, had reasonable cause to believe that his or her conduct was unlawful. 

(c) The Beneficiary shall cooperate with the person, persons or entity making such determination with respect to the Beneficiary’s entitlement to
indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the
Beneficiary and reasonably necessary to such determination. 

  
 5. 

 (d) Partial Indemnification. If the Beneficiary is entitled under any provision of this Agreement to
indemnification by the Company for some or a portion of the Expenses and Losses, in each case with respect to an Indemnifiable Claim, paid in settlement actually and reasonably incurred by or on behalf of the Beneficiary in connection with any Claim
but not, however, for the total amount thereof, the Company shall nevertheless indemnify the Beneficiary for the portion of such Expenses or Losses, in each case with respect to an Indemnifiable Claim, to which the Beneficiary is entitled. 

6. Payment by Company 
 To the fullest extent
permitted by applicable laws and regulations and provided always that the Beneficiary has acted in good faith and within his or her capacities as a Director or Officer of the Company, in the event that a Beneficiary shall not be indemnified for all
the Expenses and Losses, in each case with respect to an Indemnifiable Claim, due to (a) the failure of the Company to obtain or maintain the D&O Insurance Policy in accordance with this Offer, as well as if the maximum insurance coverage
shall be exceeded or (b) the failure of the D&O Insurance Policy to pay the Expenses or Losses, in each case with respect to an Indemnifiable Claim, the Company shall pay in full to the Beneficiary the amount of any such Expenses and
Losses, in each case with respect to an Indemnifiable Claim, to which the Beneficiary is entitled to be reimbursed or shall pay the difference between the amount received by the Beneficiary from the Insurance Company and such amount of reimbursement
of the Expenses and Losses, in each case with respect to an Indemnifiable Claim, to which it is so entitled, as the case may be. 
 7. Subrogation;
Primacy of Indemnification 
 Except as provided for below, in the event of payment by the Company to Beneficiary under the Offer, the Company shall
be subrogated to the extent of such payment to all of the rights of recovery of Beneficiary, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents
necessary to enable the Company effectively to bring suit to enforce such rights. 
 [Note to draft: This following paragraph should only be inserted for
those with a fund indemnity] 
 The Company hereby acknowledges that the Beneficiary has certain rights to indemnification, advancement of Expenses
and/or insurance provided by the Fund Indemnitors. The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Beneficiary are primary and any obligation of the Fund Indemnitors to advance expenses or to
provide indemnification for the same expenses or liabilities incurred by Beneficiary are secondary), (ii) to the extent required by this Agreement it shall advance the full amount of Expenses incurred by Beneficiary and be liable for the full
amount of all Expenses to the fullest extent permitted by applicable laws and regulations and as required by the terms of this Agreement (or any other agreement between the Company and Beneficiary), without regard to any rights Beneficiary may have
against the Fund Indemnitors, and, (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all Claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect
thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Beneficiary with respect to any Claim for which Beneficiary has sought indemnification from the Company shall affect the foregoing and the Fund
Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Beneficiary against the Company. The Company and Beneficiary agree that the Fund Indemnitors are
express third party beneficiaries of the terms hereof. 

  
 6. 

 8. Right to Payment Upon Application 

Subject to the terms and conditions of Section 5 hereof, all payment under the Offer, including relating to the reimbursement of the Expenses or any
advances of Expenses or payment of Losses, in each case with respect to an Indemnifiable Claim, shall be paid by the Company, or on its behalf, within 30 days after a written Claim for payment has been received by the Company. Expenses reasonably
incurred by the Beneficiary in connection with successfully establishing the right to payment according to the Offer, in whole or in part, shall also be paid by the Company, to the fullest extent permitted by applicable laws and regulations. 

9. Offer Not Exclusive 
 This Offer shall not be
deemed exclusive of any other rights to which the Beneficiary may be entitled under any agreement, any vote of shareholders or disinterested directors, statute, or otherwise. 

10. Notices 
 10.1. Any notices served pursuant to
this Offer shall be sent by registered mail with return receipt requested or delivered by hand against receipt if to the Company to the registered office, if to the Beneficiary to the address indicated below at the end of this Offer. 

10.2. Any change of address shall be notified by the relevant party to the other party by registered mail with return receipt requested or delivered by hand
against receipt within fifteen (15) days of the actual date of change of address. 
 10.3. Notices shall be deemed to have been received on the date of
reception of the registered letter, as evidenced by the return receipt or, as the case may be, of the letter delivered by hand, as evidenced by the receipt. 

11. Amendments- Assignment 
 11.1. No alteration
of, amendment to or waiver of any of the provisions of this Offer shall be binding on any of the parties unless it is written and executed by a duly authorized representative of each of the parties. 

11.2. This Offer may not be assigned by any party hereto except with the prior written consent of the other party. Without limiting the generality or effect
of the foregoing, the Beneficiary’s right to receive payments hereunder shall not be assignable, whether by pledge, creation of a security interest or otherwise, other than by a transfer by the Beneficiary’s will or by the laws of descent
and distribution, and, in the event of any attempted assignment or transfer contrary to this Section 11.2, the Company shall have no liability to pay any amount so attempted to be assigned or transferred. 

12. Successors 
 The legal representatives of the
parties or their successors shall be bound by and may rely on all the terms of the Offer. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation, reorganization or otherwise) to all or substantially
all of the business or assets of the Company, by agreement in form and substance satisfactory to the Beneficiary and his or her counsel, expressly to assume and agree to perform this Agreement in the same manner and to the same extent the Company
would be required to perform if no such succession had taken place. This Agreement shall be binding upon and inure to the benefit of the Company and any successor to the Company, including without limitation any person acquiring directly or
indirectly all or substantially 

  
 7. 

 
all of the business or assets of the Company whether by purchase, merger, consolidation, reorganization or otherwise (and such successor will thereafter be deemed the “Company”
for purposes of this Agreement), but shall not otherwise be assignable or delegatable by the Company. This Agreement shall inure to the benefit of and be enforceable by the Beneficiary’s personal or legal representatives, executors,
administrators, heirs, distributees, legatees and other successors. 
 13. Miscellaneous Provisions 

13.1. Term of Agreement. This Agreement shall continue until and terminate upon the later of (a) ten years after the date that the Beneficiary shall have
ceased to serve as a Director or Officer of the Company or a Subsidiary or, at the request of the Company, as a director, officer, partner, trustee, member, employee or agent of another corporation, partnership, joint venture, trust, limited
liability company or other enterprise or (b) the final termination of all Claims pending on the date set forth in clause (a) in respect of which the Beneficiary is granted rights of indemnification or advancement of Expenses hereunder and
of any Claim commenced by the Beneficiary pursuant to Section 8 of this Agreement relating thereto. 
 13.2. The parties agree that the provisions
contained in the preamble and Exhibit hereto form an integral part of the Offer. 
 13.3. Should any of the provisions of this Offer be held null and void
or unenforceable for any reason whatsoever, the parties undertake to use their best efforts to remedy the causes of such nullity, so that, except where such is impossible, the Offer shall remain in force without any discontinuity. 

13.4. The parties agree to provide any information as well as to execute and to deliver all documents reasonably required for the performance of this Offer.

 14. Applicable Law 
 This Offer shall be
governed as to its validity, construction and performance in accordance with the laws of the Republic of France. 
 15. Disputes 

Any dispute arising from the Offer or which are a result or a consequence thereof shall be made subject to the jurisdiction of the Tribunal de Commerce de
Paris. 
  

	
	Executed in
	
	On
	
	In two (2) original copies
	
	  

	By
	CEO (Directeur Général)

  
 8. 

 Accepted by 

Residing at 
 On 

being a Director or an Officer of the Company, as these terms are defined in the Offer 

who hereby declares that he or she: 
  

	 	•	 	has a good and fair knowledge of the terms, conditions and exclusions of the Offer; 

  

	 	•	 	is fully aware that applicable French laws and regulations limit a company’s ability to indemnify its directors against liability; 

 

	 	•	 	is fully aware that U.S. securities laws may also limit a company’s ability to indemnify in respect of liabilities arising under U.S. securities laws; and 

 

	 	•	 	formally and irrevocably accepts the Offer, as it stands. 

  
 9.ex10-1.htm

Exhibit 10.1

AMENDMENT NO. 1 TO

MEMORANDUM OF UNDERSTANDING

 

       THIS AMENDMENT NO. 1 TO MEMORANDUM OF UNDERSTANDING (this “Amendment”), dated as of October 12, 2014, is made by MetaStat, Inc., a Nevada corporation (“MetaStat” or the “Licensor”), MetaStat BioMedical, Inc., a Delaware corporation and a wholly-owned subsidiary of MetaStat (the “Subsidiary”), and Northstar Beacon, LLC, a Delaware limited liability company (“NORTHSTAR”), which intends to assign all of its right, title and interest in the MOU (as defined below) to ASET Therapeutics, LLC, a California limited liability company (“ASET”), which has not yet been formed (for purposes hereof, all references to the “Licensee” herein shall refer to NORTHSTAR and, upon its assignment of rights in the MOU to ASET, shall refer to ASET, and NORTHSTAR, ASET, MetaStat (or the Licensor) and the Subsidiary, shall be collectively referred to herein as the “Parties”).

 

RECITALS

 

WHEREAS, on July 14, 2014, MetaStat and the Subsidiary entered into a binding Memorandum of Understanding (the “MOU”) with the Licensee, which MOU sets forth certain understandings, rights and obligations of the Parties with respect to the proposed grant by MetaStat to the Licensee of an exclusive assignment and/or license of certain of MetaStat’s therapeutic assets pursuant to a sublicense agreement to be entered into by the Parties (the “License Agreement”); and

 

WHEREAS, the Parties desire to amend certain provisions of the MOU, as amended by this Amendment, as described herein.

 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

 

AMENDMENT

 

1. Capitalized Terms.  Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the MOU.

 

2. Amendments to MOU.

 

(a) The first sentence of Section 4(b) of the MOU is hereby deleted and the following shall be substituted in lieu thereof:

 

“(b)           No later than December 31, 2015, Licensor shall make a $1 million preferred stock equity investment in exchange for a 20% equity interest (on a fully diluted, as converted basis) in ASET for use in developing the ASE therapeutics platform and drug discovery programs.  ASET shall not sell, transfer, assign or dispose of all or any portion of the Assets prior to MetaStat owning such 20% equity interest (on a fully diluted, as converted basis) in ASET.”

 

(b) Section 8(b) of the MOU is hereby deleted and the following shall be substituted in lieu thereof:

 

“(b)           NORTHSTAR (or its affiliates) shall invest $1 million in the Subsequent Financing (or a separate financing on substantially similar terms) no later than December 31, 2015.  In the event NORTHSTAR (or its affiliates) does not invest an aggregate of $1.25 million in MetaStat by December 31, 2015 (it being acknowledged that as of the date of this Amendment, NORTHSTAR has invested $250,000), the License Agreement shall terminate, the Assets shall automatically revert back to MetaStat and Dr. Epstein shall again be subject to the same non-compete agreement currently contained in his Advisory Agreement with MetaStat.”

 

  

-1-

  

(c) Section 9(b) of the MOU is hereby deleted in its entirety.

 

(d) Section 10 of the MOU is hereby deleted and the following shall be substituted in lieu thereof:

 

“10.  Continuation of SUNY Stony Brook operations.  ASET shall be responsible for all costs and expenses up to a maximum of $50,000 per month for all operations at SUNY Stony Brook commencing on October 15, 2014 until such time that this MOU terminates.  Such payments shall be made monthly by ASET to MetaStat upon the invoicing thereof until the License Agreement is executed.  Following the execution of the License Agreement, ASET shall make such payments directly to the appropriate third parties.  In addition, NORTHSTAR (or its affiliates) shall pay to MetaStat $150,000 no later than March 1, 2015 to reimburse MetaStat for certain costs and expenses incurred by MetaStat in connection with maintaining the operations at SUNY Stony Brook.”

 

(e) Section 11(f) of the MOU is hereby deleted and the following shall be substituted in lieu thereof:

 

“(f)           The Parties shall use their best efforts to execute the License Agreement and consummate the transactions contemplated hereby on commercially reasonable terms within 90 days of the date hereof; provided, however, in the event the Parties are in the process of good faith negotiations at the end of such ninety (90) day period, MetaStat shall have the right to extend the period to finalize negotiation and execute the License Agreement for an additional thirty (30) days.”

 

3. Ratification.  Except as expressly amended hereby, all of the terms, provisions and conditions of the MOU are hereby ratified and confirmed in all respects by each Party hereto and, except as expressly amended hereby, are, and hereafter shall continue, in full force and effect.

 

4. Entire Agreement.  This Amendment and the MOU constitute the entire agreement of the Parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements and understandings, both written and oral, between the Parties with respect thereto.

 

5. Conflicting Terms.  In the event of any inconsistency or conflict between the MOU and this Amendment, the terms, conditions and provisions of this Amendment shall govern and control.

 

6. Amendments.  This Amendment may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same agreement.  Delivery by fax or electronic image of an executed counterpart of a signature page to this Amendment shall be effective as delivery of an original executed counterpart of this Amendment.

 

7. Counterparts.  This Amendment may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same agreement.

 

8. Governing Law.  This Amendment shall be governed by and construed in accordance with the laws of the State of New York, without regard to the laws that might otherwise govern under applicable principles of conflicts of law. Each of the Parties hereto irrevocably consents to the exclusive jurisdiction of the federal court for the Southern District of New York and the New York State Supreme Court located in New York County, New York, in connection with any matter based upon or arising out of this Amendment or the matters contemplated herein, and also agrees that process may be served upon them in any manner authorized by the laws of the State of New York for such persons and waives and covenants not to assert or plead any objection which they might otherwise have to such jurisdiction and such process.

[Signature pages follow]

  

-2-

  

 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Memorandum of Understanding as of the date set forth above.

 

 

METASTAT, INC.

 

By:  /s/ Oscar L. Bronsther M.D.

        Name:  Oscar L. Bronsther M.D.

        Title: Chief Executive Officer

 

METASTAT BIOMEDICAL, INC.

 

By:  /s/ Oscar L. Bronsther M.D.

        Name: Oscar L. Bronsther M.D.

        Title: Chief Executive Officer

 

 

NORTHSTAR BEACON, LLC

 

By:  /s/ David M. Epstein, Ph.D.

David M. Epstein, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]